Biogen has entered into a multi-year research collaboration with Rodin Therapeutics. The collaboration will focus on therapies for central nervous system diseases, particularly neurodegenerative conditions such as Alzheimer's disease. As part of the agreement, Biogen will have the option to acquire Rodin at certain pre-defined milestones at pre-negotiated terms, including total upfront and milestone payments of up to $485 million.